^
Association details:
| Biomarker: | ISLR overexpression |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The usefulness of meflin expression in cancer-associated fibroblasts as a predictive marker for immune checkpoint inhibitor in clear cell renal cell carcinoma.
Published date:
02/13/2023
Excerpt:
Analysis revealed that 9 (69.23%) of 13 Meflin-high patients responded to ICI. In contrast, none (0%) of 8 Meflin-low patients showed any significant response (p-value: 0.0046). Furthermore, Kaplan–Meier survival analysis revealed, the Meflin-high group had a significantly favorable prognosis in OS (p-value:0.0137, hazard ratio 0.2959[0.06933 to 0.7097])...This analysis concluded that Meflin is a good predictive biomarker for ICI in ccRCC.
DOI:
10.1200/JCO.2023.41.6_suppl.699